R&S GETS NEW CANCER DRUG
By Adnews Staff
Rubel & Schwab Communications of Toronto won more business from Zeneca Pharma of Mississauga, Ont. last week. The agency will be handling advertising for Tomudex, a new treatment for advanced colorectal cancer, still awaiting Health Canada approval although it is sold in other countries. According to the Canadian Cancer Society, colorectal cancer is the third most common type of cancer causing death in Canada. The agency won the drug ad assignment in a competition with two other Toronto agencies, Anderson Advertising and LBJ Advertising. R&S already has the Zoladex, Zestril and Zestoretic brand assignments from Zeneca.
« Back Next »
Comments
blog comments powered by Disqus